Developer docs
API playgroundTry for free, no card

Search company profiles

Panbela Therapeutics

Full company profile

uuid0002dek

Namestring
Panbela Therapeutics
Legal namestring
Panbela Therapeutics, Inc.
Websiteurl
panbela.com
Company typeenum
Public
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPonte Vedra Beach, United States
HQ citystring
Ponte Vedra Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceuticals, oncology therapeutics, cancer drug development, small molecule pharmaceuticals, pancreatic cancer treatment
Industry1 code
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Revenue
TypeOne Time License
Description

Pre-commercial stage; no current revenue from product sales as therapeutics are in clinical development phase

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Panbela Therapeutics is a clinical-stage biopharmaceutical company developing small molecule pharmaceutical candidates for oncology indications, with a primary focus on pancreatic ductal adenocarcinoma and other solid tumors. The company's pipeline includes Ivospemin (SBP-101) and Flynpovi, which are undergoing clinical trials. The company is pre-commercial and has no approved or revenue-generating products.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Panbela Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapeutics. The company's product portfolio includes Ivospemin (SBP-101) and Flynpovi, both in active clinical development for various cancer indications. The company has pursued strategic transactions including the acquisition of Cancer Prevention Pharmaceuticals Inc. in 2022 to expand its pipeline, and divested its pediatric neuroblastoma program (eflornithine) to US WorldMeds in 2023.

Product and service2 records
1Ivospemin (SBP-101)
CategoryClinical-Stage Oncology Therapeutic
Description

Ivospemin (SBP-101) is a clinical-stage small molecule therapeutic compound being developed by Panbela Therapeutics for the treatment of various cancers, including oncology indications in the company's pipeline with ongoing clinical trials.

2Flynpovi
CategoryClinical-Stage Oncology Therapeutic
Description

Flynpovi is a clinical-stage therapeutic compound being developed by Panbela Therapeutics for cancer treatment as part of the company's ongoing clinical development efforts in its oncology portfolio.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-07-19
Description

Panbela divested assets related to its pediatric neuroblastoma program to US WorldMeds, a Kentucky-based pharmaceutical company, for up to $9.5 million. The deal involves milestone payments based on clinical development, regulatory approval, and sales of eflornithine, a drug developed for neuroblastoma.

2Cancer Prevention Pharmaceuticals, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-22
Description

Panbela Therapeutics announced acquisition of Cancer Prevention Pharmaceuticals, Inc., expected to close by Q2 2022. The merger aims to expand the company's pipeline and develop therapeutics for various cancers, including a fully funded registration trial.

globenewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage small-molecule oncology company developing therapeutics for solid tumors including GI malignancies. Comparable size, public-listing profile, and dependence on incremental financing to advance a pre-commercial pipeline.

TypeBroad incumbent
Description

Public specialty oncology company commercializing and developing small-molecule cancer therapies. While larger and commercial-stage, it provides a comparable business model of small-molecule oncology asset development, registration trials, and public-market financing.

TypeDirect peer
Description

Clinical-stage, small-cap oncology company also developing therapeutics for difficult-to-treat cancers including pancreatic cancer. Comparable in being a publicly traded, sub-scale biotech where pipeline assets and licensing deals drive valuation, with similar funding-raises/dilution dynamics.

TypeDirect peer
Description

Clinical-stage small-molecule oncology biotech developing candidates for hard-to-treat solid tumors, including pancreatic and GI cancers. Comparable in scale, public listing, and reliance on clinical readouts and equity raises to advance pipeline.

TypeEmerging player
Description

Public clinical-stage precision oncology company developing small-molecule therapies with a focus on gastrointestinal tumor subtypes and rare oncology indications. Comparable in clinical-stage profile and small-cap public-market financing strategy.

TypeBroad incumbent
Description

Specialty pharmaceutical company developing and commercializing small-molecule therapeutics, including in gastrointestinal and pancreatic-related indications. Comparable in small-molecule specialty pharma orientation, though RedHill is more advanced commercially.

7AVEO Pharmaceuticals
TypeBroad incumbent
Description

Oncology-focused company with small-molecule therapeutics targeting cancers including GI malignancies. Comparable in clinical-stage small-molecule oncology development with public-listing and financing dynamics similar to Panbela's.

TypeEmerging player
Description

Public clinical-stage biotechnology company developing therapeutics for cancer, including solid tumor indications. Comparable as a micro-cap, clinical-stage biotech sustaining R&D through equity issuances while pursuing oncology pipeline readouts.

TypeEmerging player
Description

Clinical-stage developer of small-molecule oncology therapies with active programs in pancreatic and other solid tumors. Directly comparable in modality (small-molecule drug development), indication (pancreatic cancer), and pre-commercial profile.

TypeDirect peer
Description

Pre-revenue clinical-stage oncology biotech whose lead program was a small-molecule therapy for metastatic pancreatic cancer. Comparable as a micro-cap public company developing novel small-molecule oncology drugs in highly underserved indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Panbela Therapeutics

Clinical-Stage Oncology Biopharmaceuticalspanbela.com

Panbela Therapeutics firmographics

Firmographics
Name
Panbela Therapeutics
Legal name
Panbela Therapeutics, Inc.
Website
https://panbela.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Panbela Therapeutics industry classification

Industry
Product category
Clinical-Stage Oncology Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • Oncology therapeutics
  • Cancer drug development
  • Small molecule pharmaceuticals
  • Pancreatic cancer treatment

Where Panbela Therapeutics is headquartered

Location

Headquarters

HQ city
Ponte Vedra Beach
HQ country
United States
HQ region
North America

Markets served

Panbela Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Revenue: Pre-commercial stage; no current revenue from product sales as therapeutics are in clinical development phase

Go-to-market motion1 record

Marketing channels1 record

Panbela Therapeutics product offering

Product offering

Core offering

Panbela Therapeutics is a clinical-stage biopharmaceutical company developing small molecule pharmaceutical candidates for oncology indications, with a primary focus on pancreatic ductal adenocarcinoma and other solid tumors. The company's pipeline includes Ivospemin (SBP-101) and Flynpovi, which are undergoing clinical trials. The company is pre-commercial and has no approved or revenue-generating products.

Product overview

Panbela Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapeutics. The company's product portfolio includes Ivospemin (SBP-101) and Flynpovi, both in active clinical development for various cancer indications. The company has pursued strategic transactions including the acquisition of Cancer Prevention Pharmaceuticals Inc. in 2022 to expand its pipeline, and divested its pediatric neuroblastoma program (eflornithine) to US WorldMeds in 2023.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ivospemin (SBP-101) Ivospemin (SBP-101) is a clinical-stage small molecule therapeutic compound being developed by Panbela Therapeutics for the treatment of various cancers, including oncology indications in the company's pipeline with ongoing clinical trials.
  • Flynpovi Flynpovi is a clinical-stage therapeutic compound being developed by Panbela Therapeutics for cancer treatment as part of the company's ongoing clinical development efforts in its oncology portfolio.

Companies that use Panbela Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Panbela Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Panbela Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • US WorldMedsminorStrategic or Co-development Partner · 19 July 2023Panbela divested assets related to its pediatric neuroblastoma program to US WorldMeds, a Kentucky-based pharmaceutical company, for up to $9.5 million. The deal involves milestone payments based on clinical development, regulatory approval, and sales of eflornithine, a drug developed for neuroblastoma.
  • Cancer Prevention Pharmaceuticals, Inc.coreStrategic or Co-development Partner · 22 February 2022Panbela Therapeutics announced acquisition of Cancer Prevention Pharmaceuticals, Inc., expected to close by Q2 2022. The merger aims to expand the company's pipeline and develop therapeutics for various cancers, including a fully funded registration trial.

Scale indicators9 records

Recent moves6 records

Expansion highlights4 records

Panbela Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cardiff Oncology: Clinical-stage small-molecule oncology company developing therapeutics for solid tumors including GI malignancies. Comparable size, public-listing profile, and dependence on incremental financing to advance a pre-commercial pipeline.
  • Rafael Holdings: Clinical-stage, small-cap oncology company also developing therapeutics for difficult-to-treat cancers including pancreatic cancer. Comparable in being a publicly traded, sub-scale biotech where pipeline assets and licensing deals drive valuation, with similar funding-raises/dilution dynamics.
  • Moleculin Biotech: Clinical-stage small-molecule oncology biotech developing candidates for hard-to-treat solid tumors, including pancreatic and GI cancers. Comparable in scale, public listing, and reliance on clinical readouts and equity raises to advance pipeline.
  • Tyme Technologies: Pre-revenue clinical-stage oncology biotech whose lead program was a small-molecule therapy for metastatic pancreatic cancer. Comparable as a micro-cap public company developing novel small-molecule oncology drugs in highly underserved indications.

Broad incumbents

  • Puma Biotechnology: Public specialty oncology company commercializing and developing small-molecule cancer therapies. While larger and commercial-stage, it provides a comparable business model of small-molecule oncology asset development, registration trials, and public-market financing.
  • RedHill Biopharma: Specialty pharmaceutical company developing and commercializing small-molecule therapeutics, including in gastrointestinal and pancreatic-related indications. Comparable in small-molecule specialty pharma orientation, though RedHill is more advanced commercially.
  • AVEO Pharmaceuticals: Oncology-focused company with small-molecule therapeutics targeting cancers including GI malignancies. Comparable in clinical-stage small-molecule oncology development with public-listing and financing dynamics similar to Panbela's.

Emerging players

  • Cogent Biosciences: Public clinical-stage precision oncology company developing small-molecule therapies with a focus on gastrointestinal tumor subtypes and rare oncology indications. Comparable in clinical-stage profile and small-cap public-market financing strategy.
  • Phio Pharmaceuticals: Public clinical-stage biotechnology company developing therapeutics for cancer, including solid tumor indications. Comparable as a micro-cap, clinical-stage biotech sustaining R&D through equity issuances while pursuing oncology pipeline readouts.
  • Iterion Therapeutics: Clinical-stage developer of small-molecule oncology therapies with active programs in pancreatic and other solid tumors. Directly comparable in modality (small-molecule drug development), indication (pancreatic cancer), and pre-commercial profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Panbela Therapeutics social profiles

Digital presence

Panbela Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Panbela Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Panbela Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Panbela Therapeutics funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Panbela Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panbela Therapeutics

What does Panbela Therapeutics do?

Panbela Therapeutics is a clinical-stage biopharmaceutical company developing small molecule pharmaceutical candidates for oncology indications, with a primary focus on pancreatic ductal adenocarcinoma and other solid tumors. The company's pipeline includes Ivospemin (SBP-101) and Flynpovi, which are undergoing clinical trials. The company is pre-commercial and has no approved or revenue-generating products.

Is Panbela Therapeutics a public or private company?

Panbela Therapeutics is a public company. It is classified as public and is currently operating.

When was Panbela Therapeutics founded?

Panbela Therapeutics was founded in 2011. It employs 1 to 10 people.

Where is Panbela Therapeutics based?

Panbela Therapeutics is headquartered in Ponte Vedra Beach, United States, in the North America region.

How does Panbela Therapeutics make money?

One revenue line is on record: product Revenue.

Who are Panbela Therapeutics's main competitors?

Direct peers on record are Cardiff Oncology, Rafael Holdings, Moleculin Biotech and Tyme Technologies. Broad incumbents are Puma Biotechnology, RedHill Biopharma and AVEO Pharmaceuticals. Emerging players are Cogent Biosciences, Phio Pharmaceuticals and Iterion Therapeutics.

Does Panbela Therapeutics have an API?

No public API is recorded for Panbela Therapeutics.

What industry is Panbela Therapeutics in?

Panbela Therapeutics's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsPanbela Therapeutics (PBLA) Expected to Release Earnings on FridayPanbela Therapeutics is expected to release earnings on Friday, November 13th, with analysts projecting a loss of $2,640 per share. The stock opened at $0.01, with a 12-month range of $0.00 to $0.10. The company focuses on polyamine metabolism therapies, including ivospemin for pancreatic cancer.Defense WorldCritical Review: Vaccinex (NASDAQ:VCNX) and Panbela Therapeutics (OTCMKTS:PBLA)This article presents a comparative financial analysis of Vaccinex (NASDAQ:VCNX) and Panbela Therapeutics (OTCMKTS:PBLA), two clinical-stage biotech companies, across eight factors including profitability, valuation, and ownership. Vaccinex reported $388,000 in revenue versus Panbela's N/A, with both companies showing negative net income (Vaccinex: -$20.25M; Panbela: -$25.26M). The analysis concludes that Vaccinex outperforms Panbela on five of the eight comparison factors, with Vaccinex showing higher institutional ownership (50.1% vs 4.4%) and lower beta (1.1 vs 1.76).Defense WorldFinancial Analysis: Panbela Therapeutics (OTCMKTS:PBLA) & PyroGenesis Canada (NASDAQ:PYRGF)This article presents a comparative financial analysis between Panbela Therapeutics (OTCMKTS:PBLA) and PyroGenesis Canada (NASDAQ:PYRGF), examining volatility, valuation, earnings, institutional ownership, and profitability metrics. PyroGenesis Canada shows higher revenue ($9.14 million vs. N/A) and a more affordable valuation based on price-to-earnings ratio, while Panbela Therapeutics has higher institutional ownership at 4.4% compared to 0.0%. The article provides descriptive profiles of both companies, with PyroGenesis focusing on plasma-based industrial solutions and Panbela developing clinical-stage oncology therapeutics.Defense WorldComparing Panbela Therapeutics (OTCMKTS:PBLA) and MusclePharm (OTCMKTS:MSLP)This article presents a comparative financial analysis of two OTCMKTS-traded companies: Panbela Therapeutics, a clinical-stage biopharmaceutical firm developing treatments for pancreatic cancer, and MusclePharm, a sports nutrition products manufacturer. The comparison evaluates nine financial and market metrics, including profitability, institutional ownership, risk/volatility, and valuation indicators. According to the analysis, MusclePharm outperforms Panbela Therapeutics on five of the nine factors compared, though both companies show negative net income in their most recent reported periods.BioCenturyOct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastomaThe FDA’s Oncologic Drugs Advisory Committee voted 14-6 to back US WorldMeds' application for eflornithine to treat pediatric high-risk neuroblastoma, citing sufficient evidence of improved event-free survival from a single externally controlled trial. The decision comes after US WorldMeds licensed the drug from Panbela Therapeutics in July, though some panelists requested further randomized controlled trials. Additionally, ClavystBio launched a new life sciences innovation space in Singapore to support early-stage biotech ventures.GlobeNewswirePanbela Provides Business Update and Reports Q3 2024 Financial ResultsPanbela Therapeutics reported Q3 2024 financial results, including a net loss of $7.2 million and a $12.0 million financing commitment from Nant Capital. The company also initiated patient enrollment in a Phase I study for CPP-1X-S in STK11 mutant NSCLC, with its ASPIRE trial interim analysis expected in Q1 2025.GlobeNewswirePanbela Announces Oral Presentation at Digestive Disease Week (DDW):Panbela Therapeutics announced an oral presentation at Digestive Disease Week on eflornithine for gastric premalignant conditions. The Phase IIa trial showed eflornithine reduced DNA damage long-term, with 78, 69, and 55 patients reaching 6-, 18-, and 24-month outcomes. The company highlighted its pipeline, including ivospemin and Flynpovi.GlobeNewswireAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekPanbela Therapeutics announced that an abstract on eflornithine (DFMO) for gastric premalignant conditions will be presented orally at Digestive Disease Week May 18-21, 2024. The presentation is part of its collaboration with Vanderbilt University Medical Center. The company also highlighted its pipeline assets, including ivospemin and Flynpovi.GlobeNewswireDelisting of Securities of Northern Revival AcquisitionNasdaq announced delistings for Northern Revival Acquisition Corporation and several other companies, including Veradigm, Neptune Wellness Solutions, and Panbela Therapeutics. The securities of these firms had been suspended and had not traded on Nasdaq since their suspension dates.BenzingaTop 4 Health Care Stocks That Are Preparing To Pump This Month - GRI Bio (NASDAQ:GRI)This article from Benzinga Pro identifies four oversold healthcare stocks on Nasdaq with RSI values near or below 30, suggesting potential buying opportunities based on technical indicators. The four companies covered are ProSomnus (RSI 29.72, stock fell ~26% over five days), Panbela Therapeutics (RSI 29.71, stock fell ~71% over the past month), Sintx Technologies (RSI 29.66, stock fell ~55% over the past month), and GRI Bio (RSI 29.28, stock fell ~21% over five days). The article includes recent developments for each company such as ProSomnus reporting a successful pilot study, Panbela regaining Nasdaq compliance, Sintx entering a supply agreement, and GRI pricing a $5.5 million public offering.